Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic

Abstract excerpt

Oligodendrocyte death contributes to the pathogenesis of the inflammatory demyelinating disease multiple sclerosis (MS). Nevertheless, current MS therapies are mainly immunomodulatory and have demonstrated limited ability to inhibit MS progression. Protection of oligodendrocytes is therefore a desirable strategy for alleviating disease. Here we demonstrate that enhancement of the integrated stress response using...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Endoplasmic Reticulum Stress and Disease
• Share to Neuroinflammation and Neurodegeneration Mechanisms
• Share to Sirtuins and Resveratrol in Medicine